M. Cyronak

发表

Does a stable isotopically labeled internal standard always correct analyte response? A matrix effect study on a LC/MS/MS method for the determination of carvedilol enantiomers in human plasma.

Sherry Wang, M. Cyronak, Eric Yang, 2007, Journal of pharmaceutical and biomedical analysis.

Stereoselective analysis of carvedilol in human plasma using HPLC/MS/MS after chiral derivatization.

Sherry Wang, M. Cyronak, Eric Yang, 2004, Journal of pharmaceutical and biomedical analysis.

High-performance liquid-chromatographic determination of warfarin enantiomers in plasma with automated on-line sample enrichment.

W. H. Schaefer, M. Cyronak, V. Boppana, 2002, Journal of biochemical and biophysical methods.

Comparison between carvedilol and captopril in rats with partial ablation‐induced chronic renal failure

R. Ruffolo, D. Brooks, M. Cyronak, 1993, British journal of pharmacology.

Continuous intragastric delivery of fenoldopam: relationship between plasma concentration and effects on renal function.

M. Cyronak, R. Stote, J. Dubb, 1988, British journal of clinical pharmacology.

Trapping 4-fluorobenzyl chloride in human plasma with chemical derivatization followed by quantitative bioanalysis using high-performance liquid chromatography/tandem mass spectrometry.

Sherry Wang, Chester L. Bowen, M. Cyronak, 2005, Rapid communications in mass spectrometry : RCM.

Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease

M. Cyronak, S. Vakil, A. López-Gil, 1999, Pharmacotherapy.

Determination of SK&F 108566 (Teveten) in human plasma by reversed-phase high-performance liquid chromatography.

M. Cyronak, D. Lundberg, S. Knox, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Identification of fenoldopam prodrugs with prolonged renal vasodilator activity.

K. Erhard, D. Brooks, M. Cyronak, 1990, Journal of Pharmacology and Experimental Therapeutics.

The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure

M. Cyronak, C. Corder, D. Boyle, 1991, Clinical pharmacology and therapy.

A Retrospective Analysis of Fenoldopam Renal Excretion in 65 Subjects: Evidence for Possible Intrarenal Formation of Fenoldopam from Its Metabolites

M. Cyronak, R. Stote, J. Ziemniak, 1989, Pharmaceutical Research.

Simplified procedures for the determination of fenoldopam and its metabolites in human plasma by high-performance liquid chromatography with electrochemical detection: comparison of manual and robotic sample preparation methods.

M. Cyronak, J. Ziemniak, V. Boppana, 1989, Journal of chromatography.